In this paper we propose a multivariate extension of family-based association tests based on generalized estimating equations. The test can be applied to multiple phenotypes and to phenotypic data obtained in longitudinal studies without making any distributional assumptions for the phenotypic observations. Methods for handling missing phenotypic information are discussed. Further, we compare the power of the multivariate test with permutation tests and with using separate tests for each outcome which are adjusted for multiple testing. Application of the proposed test to an asthma study illustrates the power of the approach.
INTRODUCTION
Studies of association between disease outcomes and genetic markers often use samples of diseased subjects along with their parents or other family members. Such samples can be used to construct familybased association tests (FBATs) (Thomson, 1995; Zhao, 2000; Laird et al., 2001) . We use the term FBAT very generally to denote an association test which uses genetic data on family members to compute the distribution of a suitable test statistic under the null hypothesis, conditioning on the phenotypes. FBATs provide simple and powerful tests to detect linkage between a marker and a disease susceptibility locus, in the presence of linkage disequilibrium between the two loci. The best known FBAT, the TDT proposed by Spielman et al. (1993) , was developed for dichotomous disease traits under the assumption of having known genotypes for both parents and at least one affected offspring. Other tests have been suggested for quantitative phenotypes: Rabinowitz (1997) ; Allison et al. (1999) and Abecasis et al. (2000) . Approaches for multiple phenotypes or longitudinal measures of phenotypes have not been developed.
Many genetic studies collect data on a set of related phenotypes that are potentially associated with the marker loci under study. One approach is to test all phenotypes individually and to adjust the p-value for multiple testing by the bonferroni correction. In practice, correcting the p-values by Bonferroni is conservative and many genetic studies may fail to detect true associations. Modifications of the Bonferroni correction have been proposed: for example, Hochberg (1988) . Another alternative is to use permutation tests which permute the observed data under the null-hypothesis.
In the univariate phenotype setting, most FBAT statistics are based on the general likelihood-score test approach discussed in Lazzeroni and Lange (2001) ; Schaid and Sommer (1996) and Laird et al. (2000) . Here we propose a natural extension of FBATs to multivariate phenotypes based on GEE scores (Liang and Zeger, 1986) . Without making any assumptions about the distributions of the phenotypes, the multivariate FBAT test allows us to test the null hypothesis that the marker locus is not linked to any genetic locus that has an influence on the selected phenotypes. The proposed methodology is illustrated by an application to an asthma genetics study. While multiple FBAT-testing with various corrections failed to find a significant association, the multivariate test gives a significant result. Simulation experiments involving quantitative traits show that the multivariate FBAT clearly outperforms permutation tests and individual FBATs with corrections for multiple testing.
EXTENSION OF FBAT TO MULTIVARIATE DATA
In this section we will introduce an extension of FBATs for multivariate phenotypes which we subsequently refer to as FBAT-GEE. Since we compute the distribution of the test statistic conditional on the observed phenotypes, FBAT-GEE is a valid multivariate test that does not require any distributional assumption for the phenotypes. Hence FBAT-GEE can be applied directly to multiple phenotypic observations of arbitrary types: for example, dichotomous outcome variables, counts, continuous variables and to combinations of different types of variables.
For simplicity of exposition, we assume that we observe n independent families consisting of parents and one offspring, but the method extends easily to the more general case where we observe siblings and/or one or more parent is missing using the approach described in Rabinowitz and Laird (2000) . We test the null-hypothesis that a marker locus is not linked to any disease-susceptibility locus for any of m selected phenotypes. The proposed idea can easily be adapted to situations when more than one linked/unlinked loci are included. However, to outline the idea it is sufficient to discuss this simpler one-locus scenario.
Assume first that we observe one bi-allelic marker locus with alleles A and B, with x i counting the number of transmitted A alleles in the offspring of the ith family, i.e. x i = 0, 1, 2. Other choices of genotype coding are possible (Schaid and Sommer, 1994) . The parental genotypes for the ith family are denoted by p i1 and p i2 . Suppose there is a single phenotype and let the phenotypic observation for the offspring in the ith family be y i . For such setups, Lazzeroni and Lange (2001) ; Schaid and Sommer (1996) and Laird et al. (2000) pointed out that univariate FBATs can be derived quite generally from likelihood scores where the likelihood function models the phenotype Y i given the marker score x i . Under the assumption that Y i given x i can be modelled by a generalized linear model with distributions from the exponential family-for example, Bernoulli for binary traits, normal distribution for continuous traitsconditioning on the sufficient statistic for any nuisance parameter under the null-hypothesis, Lunetta et (2000) showed that the likelihood score is given by the statistic n i=1 t i x i where t i is an appropriate coding of the phenotype y i . When trios with a single affected offspring are given, setting t i = 1 yields the standard TDT proposed by Spielman et al. (1993) . When also unaffected offspring are sampled, then coding affected offspring by y i = 1 and unaffected by y i = 0 and setting t i = y i − K gives the FBAT proposed by Whittaker and Lewis (1998) where K is the population prevalence of the disease. For quantitative phenotypes y i , we define t i = y i − y where y is the sample mean and obtain so the quantitative FBAT proposed by Rabinowitz (1997) . Notice that setting t i = 0 means that the ith offspring does not contribute to the test statistic (see below).
The statistic n i=1 t i x i can then directly be utilized to construct a FBAT χ 2 , ie
(1) (Liang and Zeger, 1986; Heyde, 1997 ). The GEE score is then given by the statistic S = n i=1 x i ∆ i Var(t i ) −1 t i , where Var(t i ) is the 'working' variance matrix for the phenotypes of the ith individual, ∆ i is a diagonal matrix that depends on the model assumptions of the underlying GEE model and t i is the m-dimensional vector containing the coded trait information: for example, for continuous phenotypes t i = y i − y where y is the vector of observed sample means. With no missing phenotypic data and no covariates, the variance matrix of t i and ∆ i are identical for all subjects under H 0 , ie Var(t) ≡ Var(t i ) and ∆ ≡ ∆ i . Thus, they vanish when the score test is constructed under the null-hypothesis. Hence we define the m-dimensional centered score vectorS byS
Further, note that E S = 0. It is then easy to see that the m × m variance matrix of the vectorS is given by
So the multivariate extension of the univariate FBAT can be defined by
Asymptotic theory (Lange and Laird, 2002) therefore implies that the multivariate FBAT χ 2 FBAT−GEE is asymptotically χ 2 -distributed,
are incorporated simultaneously in the computation of χ 2 FBAT−GEE , the FBAT-GEE test uses more information than individual FBATs and should therefore be more powerful.
The interpretation of a significant FBAT-GEE test result depends on assumptions about the underlying genetic model. When one assumes that all phenotypes tested by FBAT-GEE are linked to an unobserved trait/genetic mechanism which is influenced by the tested gene, a significant FBAT-GEE can be understood as a significant result for the underlying trait/mechanism, which is expressed by the selected phenotypes.
When one assumes no shared genetic mechanism and the main purpose of FBAT-GEE is to reduce the number of comparisons by testing jointly all phenotypes in one symptom group, a significant FBAT-GEE result implies that one has to test all phenotypes of a significant group individually by FBATs to detect the associated traits. Since the individual univariate FBATs are only applied when FBAT-GEE was significant, the significance level of FBAT-GEE is maintained and is also the overall significance level. For example, assume we want to test 30 phenotypes for association at an overall significance level of α. The traits can be grouped into 5 subgroups. Then using individual FBATs, the adjusted significance level is α/30 (Bonferroni correction). However, when we first test the five groups by FBAT-GEE the adjusted significance is α/5. Assuming that one group shows significance, we test all six phenotypes within this group individually, each at an adjusted significance level of α/6. Thus, the overall significance level and the significance level in each step, FBAT-GEE and then univariate FBATs, is α.
When a multi-allelic marker locus is considered, the FBAT-GEE test extends naturally. The marker information x i becomes a p-dimensional vector giving marker information for multiple alleles,
where ⊗ denotes the Kronecker product. Note thatS is now a pm-dimensional vector. The variance ofS is a pm × pm matrix given by
) for the multiallelic case are given in Horvath et al. (2001) . The FBAT-GEE test for a multi-allelic locus can also be computed by (4) and has an asymptotic χ 2 -distribution under the null-hypothesis where the degrees of freedom are given by the rank of Var(S). Since Var (x i | p i1 , p i2 ) generally has rank p − 1, Var(S) has rank m( p − 1) as long as all phenotypes are linearly independent. It is important to note that for alternative genotypic codings, eg for dominant or recessive diseases, Var (x i | p i1 , p i2 ) may have rank p. Then Var(S) has rank mp.
The multivariate FBAT χ 2 FBAT−GEE and its validity do not depend upon any distributional assumption for the phenotypes. This model-free character of χ 2 FBAT−GEE has the great advantage that it allows us to test different trait types (e.g. binary phenotypes, continuous phenotypes, etc.) simultaneously without having to specify a statistical model which describes the dependence of the multivariate phenotypic vector y i on the marker score x i .
Note that χ 2 FBAT−GEE as defined here is a valid test for the null-hypothesis of no linkage if siblings are used, because transmissions of genes from parents to different offspring are independent when there is no linkage. For the null-hypothesis of no association in the presence of linkage, transmissions are correlated (Martin et al., 2000) . However, χ 2 FBAT−GEE can easily be modified to test for association using the empirical variance proposed by Lake et al. (2000) . Generalization of FBAT-GEE for missing parental information and/or for missing phenotypic information are also straightforward. When parental genotypic information is missing, the conditional marker mean and variance under the null-hypothesis can be computed by using the theory of family-based association tests (Rabinowitz and Laird, 2000; . When phenotypic information is missing, we have the choice between two approaches, imputing the missing phenotypes or using the GEE score of the 'observed' phenotypes. For example, the phenotypes can be imputed by the observed phenotypic mean, which is equivalent to setting t i j = 0 when t i j is defined by t i j = y i j − y j . Note that this effectively means that the ith subject contributes no information to the test statistic for the jth phenotype. A more sophisticated way would be to imputed the missing phenotypes by the EM-algorithm (Dempster et al. 1977) , estimating the mean and variance matrix from the entire sample. However, no matter which imputation technique we elect they all suffer from the conceptional drawback of being computed under the null-hypothesis. The imputed phenotypes will therefore always provide evidence for the null-hypothesis and will make the test χ 2 FBAT−GEE more conservative. On the other hand, applying imputation techniques under the alternative hypothesis would require making model assumptions about the distribution of the phenotypes.
Alternatively, in presence of missing phenotypic information, the 'observed' GEE score can be utilized. The GEE score is now given by S = n i=1 x i I i ∆ i Var(t i ) −1 t i where t i is the vector of observed traits. I i is constructed by taking a m × m identity matrix and removing the columns that correspond to the missing phenotypic information. Since the matrices ∆ i and Var(t i ) are constructed by taking ∆ and Var(t) and removing the rows and columns that correspond to the missing observations, the dimensions of ∆ i and Var(t i ) can vary between families. The variance matrix Var(t i ) and ∆ i do therefore not vanish in the construction of score test statistic and have to be estimated when the GEE score is used for the computation of the test statistic. We will apply both approaches of handling missing phenotypes, imputation techniques and 'observed' GEE scores, to the asthma study.
Further, it is important to note that χ 2 FBAT−GEE is invariant under any linear transformation. Since principal component analysis or canonical correlations are special cases of such linear transformations, they can only be useful to reduce the number of phenotypes tested. Simply transforming phenotypes will not have any effect either on the p-value or on the power.
DATA ANALYSIS: CHILDHOOD ASTHMA MANAGEMENT PROGRAM
We applied the FBAT-GEE approach to a collection of parent/child trios in the Childhood Asthma Management Program (CAMP) Genetics Ancillary Study. The CAMP study is a clinical trial of 1041 asthmatic children who were randomized to three different asthma treatments (CAMP, 1999) . Blood samples for DNA were collected from 696 complete parent/child trios from 640 pedigrees in the CAMP Ancillary Genetics Study. Baseline phenotype values, before randomization to treatment groups, were used in this analysis. Genotyping was performed at a polymorphism located at amino acid 16 of the Beta-2 Adrenergic Receptor (B2AR) gene. Previous case/control association studies have reported an association of the B2AR-16 polymorphism with various phenotypes including bronchodilator responsiveness, nocturnal asthma, and pulmonary function (the forced expiratory volume at one second of a forced expiratory maneuver, or FEV1) (Turki et al., 1995; Martinez et al., 1997; Summerhill et al., 2000) . Asthma is a clinical condition often associated with an atopic predisposition; we have selected three phenotypes related to the allergic response, including total eosinophil count, core number of positive allergy skin tests to common environmental antigens, and total serum immunoglobulin E levels (expressed as log 10 ). Asthma is also associated with a variety of abnormalities in pulmonary function, including reductions in forced expiratory flow (such as the FEV1), increased tendency for bronchoconstriction in response to chemicals such as methacholine (expressed as the natural logarithm of the provocative concentration causing a 20% reduction in FEV1 or ln(PC20)), and increased FEV1 following administration of bronchodilator medications. We included three pulmonary function phenotypes, FEV1 (expressed as percentage of predicted after bronchodilator treatment), ln(PC20) and bronchodilator responsiveness (expressed as change in FEV1 as a percentage of predicted FEV1 after bronchodilator treatment). A more comprehensive analysis of associations between B2AR-16 and baseline phenotypes will be presented separately.
We elected to test at significance level α = 0.05 whether any of the phenotypes was associated with the biallelic marker locus (B2AR-16). Missing phenotypic data was handled either by imputation or by computing FBAT-GEE based on the 'observed' GEE scores where all traits were considered to be normally distributed and the phenotypic means and variance matrix were estimated by their empirical estimators based on the observed and imputed phenotypes (EM-algorithm). The phenotypes were imputed either by setting t i j = 0 or by the EM-algorithm (Dempster et al. 1977) . Of the 696 families, 439 had at least one heterozygous parents and thus contribute to the test statistic.
Initially, we tested for association between B2AR-16 with each phenotype separately, using the FBAT program http://www.biostat.harvard.edu/∼fbat/default.html). The p-values for family-based association testing of each phenotype separately are shown in Table 1 . Although there was some evidence for association of B2AR-16 to FEV1, after Bonferroni correction none of the phenotypes were significant (α Bonferroni = 0.008).
Subsequently, we used FBAT-GEE, which is also implemented in the FBAT program, to test for association within the two groups of phenotypes, atopy-related and pulmonary function phenotypes ( Table 2 ). The FBAT-GEE was computed three times: by setting t i j = 0, imputing missing values by the EM-algorithm and based on observed GEE scores; since two groups were tested, the significance level was α Bonferroni = 0.025. For all approaches of handling missing phenotypic information at this level of significance, a significant association was detected between B2AR-16 and pulmonary function phenotypes; no significant association to atopy-related phenotypes was detected. The significant p-value (0.012) obtained by FBAT-GEE based on 'observed' GEE scores was slightly smaller than the p-value obtained by the imputation methods (0.021 and 0.018). Since the imputation methods used here assume that the null-hypothesis is true, it is likely that FBAT-GEE based on such imputed values is conservative. On the other hand, using the GEE scores does not require such assumption. Further studies are desirable to assess the optimal strategy.
Since the pulmonary function phenotypes showed a significant FBAT-GEE result, we test the phenotypes of this group individually. The overall significance level α = 0.05 is maintained when the individual FBAT for the three phenotypes achieve jointly a significance level of α = 0.05. We therefore use the Bonferroni correction again. The individual FBATs have to be significant at α = 0.05/3 = 0.016. Thus, FEV1 reaches overall significance (Table 1) . Because FEV1 is not highly correlated with other pulmonary function phenotypes, we conclude that there is good evidence for an effect of B2AR-16 only on FEV1, and no evidence for atopy phenotypes or other pulmonary function phenotypes. 
POWER COMPARISON BETWEEN FBAT-GEE, PERMUTATION TESTS AND MULTIPLE ADJUSTED FBAT-TESTING
In this section we assess the power of the FBAT-GEE test by simulation experiments and compare it with permutation tests and with multiple FBAT-testing where the p-value is adjusted either by Bonferroni correction (BC) or by Hochberg (1988) correction (HC). The HC-method is a sequential version of the BC-method. The scenarios addressed in this simulation experiment are motivated by the asthma study. We assume that a sample of asthmatics and their parents are available; we observe the genotypes of all family members. For each asthmatic, two groups of three normally distributed phenotypes are measured. We want to test each group for a potential association with the marker locus.
We generate trios with a biallelic marker locus by drawing the parental genotypes p 1 and p 2 from the Bionomial distribution Bi(2, p) where p is the allele frequency of the disease gene in the population. Using Mendelian transmissions, the genotype of the individual x i is then simulated based on the parental genotypes. The phenotypic vector Y i for each individual is obtained by generating samples from a multivariate normal distribution, i.e. Y i ∼ N ((a 1 x i , a 2 x i , a 3 x i ) , Σ) , where a j , j = 1, 2, 3 are the additive effects for the jth phenotype and Σ = σ 2 i j is the (3 × 3) variance matrix. The strength of an additive effect relative to the phenotypic variance is expressed by the heritability h 2 j (Falconer and Mackay, 1997) , which is is defined as the the proportion of phenotypic variation explained by the genetic variation, ie h 2 j = Var a j X i /Var Y i j . This equation can be solved for a j and an analytical expression for a j given h 2 j can be obtained, a j = σ j j h j /2 p (1 − p) 1 − h j . In the asthma study we analyzed two groups of phenotypes, pulmonary function phenotypes and atopyrelated phenotypes. The empirical correlation matrices of these groups are used in the simulation study as correlation matrices for the phenotypes; these are given in Table 3 . For simplicity, we assume the variances σ 2 ii = 1 and use the correlation matrices of those groups as variance matrices. We conduct the first simulation study under the assumption that all three phenotypes of the pulmonary function group are associated with the marker locus. We therefore set the heritability of all three phenotypes to 0.05, ie h 1 = h 2 = h 3 = 0.05, and Σ equal to the correlation matrix Σ 1 of the pulmonary function phenotypes (Table 3) . We generate n = 300 trios where each offspring has three phenotypes.
Then a number of tests are applied. First, we compute FBAT-GEE for the first phenotype. For a univariate phenotype, FBAT-GEE is identical to the continuous FBAT proposed by Rabinowitz (1997) . Then we compute FBAT-GEE for the first two phenotypes and finally FBAT-GEE is calculated for all three phenotypes. All observed FBAT-GEE values are compared to the appropriate threshold values. Then the same sets of phenotypes are tested for association by testing the phenotypes individually by the univariate continuous FBAT (Rabinowitz, 1997) and comparing the observed test statistic values to threshold values that have been adjusted either by HC or by BC. Further, a permutation test is computed where the phenotypic vectors are kept fixed and the trio's genotypes are randomly permuted. As for FBAT-GEE, the permutation test was computed for one, two and three phenotypes. This procedure is repeated for 10 6 replicates. The allele frequency is assumed to be p = 0.3, 0.1, 0.05. The significance level is α = 0.01. The results are given in Table 3 . permutation tests and the individual FBATs adjusted either by HC or BC. Further, we estimated the true significance levels for α = 0.01 (Table 4) . The same simulation experiment is repeated for the second group of phenotypes of the asthma study. For the atopy-related phenotypes, we assume that only the first phenotype is associated with marker locus, while the other two phenotypes are not, i.e. h 1 = 0.05, h 2 = h 3 = 0. The correlation matrix is now given by Σ 2 (Table 3 ). The estimated power for this scenario is shown in Table 3 .
For both scenarios, Table 3 shows that FBAT-GEE is preferable to permutation tests and testing by individual FBATs and adjusting either by HC or by BC. When all phenotypes are associated with the marker locus, the power of FBAT-GEE increases much faster than that of the other tests. On the other hand, when only the first phenotype is associated with the locus, the power of FBAT-GEE drops more slowly than the power for the other tests as further unassociated phenotypes are added. The overall ranking of the tests which can be observed in each simulation experiment is FBAT-GEE, permutations tests, individually testing with HC and individually testing with BC. While FBAT-GEE performs considerably better than permutation tests, permutation tests clearly outperform individually testing. However, HC does only a little bit better than BC.
The empirical significance levels for multiple testing with HC or BC are very close to those of FBAT-GEE. This suggests that the higher power of FBAT-GEE is due to the fact that FBAT-GEE considers all phenotypes simultaneously rather than uses only the information of one phenotype at a time. This property makes FBAT-GEE a promising test that has many applications to multivariate data, repeated measures and longitudinal data. Table 3 also shows that FBAT-GEE and individual FBATs adjusted by corrections become more and more conservative for smaller values of p. In a total population sample a smaller allele frequency p is equivalent to a smaller number of informative families. Further, we observe in Table 4 that the estimated significance level for FBAT-GEE decreases when the number of phenotypes m increases. This observation indicates that the convergence speed of FBAT-GEE towards its asymptotic distribution depends on the number of phenotypes, ie the distribution of FBAT-GEE converges more slowly for increasing m.
The permutation test is slightly anti-conservative. In addition, we note that applying the permutation test is much more complex with multiple siblings, missing parents and/or phenotypes, etc or when linkage is present.
DISCUSSION
In this paper we have presented a multivariate approach to transmission disequilibrium tests that allows us to test several phenotypes simultaneously for linkage with one marker locus. Although different trait types can be tested simultaneously, no assumptions about their distributions have to be made. Further, various extensions of the FBAT-GEE approach are possible. Since we only have to know the marker mean and variance under the null-hypothesis for the computation of the test statistic, the FBAT-GEE approach can easily be adapted to scenarios with multiple offspring per family and missing parental information, and testing for linkage disequilibrium under the assumption of linkage. When phenotypic data are missing the FBAT-GEE approach can easily be extended either by imputation methods or by 'observed' GEE scores.
We have compared the power of FBAT-GEE, permutation tests and multiple testing with HC and BC by simulation experiments for scenarios derived from the asthma data set. Under these scenarios FBAT-GEE proved to be substantially more powerful than the other tests. We also repeated these simulations for combinations of different trait types: for example, counts, binary outcomes and percentages. Thereby we used the multivariate normal distribution to generate random numbers and then 'discreteized' the outcomes. The results of these simulation studies suggest that the superiority of the FBAT-GEE over the other tests decreases with the discreteness of the phenotypes. For example, while FBAT-GEE is clearly more powerful for count and percentage variables, this advantage becomes less relevant for binary outcome variables. Further simulation studies also supported the assumption that 'observed' GEE scores are a more powerful way of handling missing phenotypic information than imputation methods.
We have applied this novel approach for inclusion of multiple phenotypes to a relevant example in asthma genetics. For many genetic epidemiological studies, comprehensive phenotypic data is collected. However, use of multiple phenotypes in independent statistical tests requires correction for the multiple testing performed. Our proposed method provides a more efficient use of multiple phenotypes that does not require costly corrections for multiple comparisons. Further study will be required to determine the optimal approach to group phenotypes for such analyses. So far, our experience with real data sets is that FBAT-GEE is more powerful than individual FBAT testing when the phenotypes can be grouped into symptom groups with up to eight or nine phenotypes in each group: for example, here pulmonary function phenotypes and atopy-related phenotypes. Then testing each group individually and adjusting for multiple testing seems to be far more powerful than testing each phenotype individually (Demeo et al (in preparation)). A GEE approach for population data is discussed in Lange and Whittaker (2002) .
